Overview

  • Product name
    Anti-Warfarin antibody
  • Description
    Sheep polyclonal to Warfarin
  • Tested applications
    Suitable for: ELISA, Competitive ELISA, Purificationmore details
  • Immunogen

    Warfarin conjugated to Bovine thyroglobulin.

Properties

  • Form
    Liquid
  • Storage instructions
    Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles.
  • Storage buffer
    Preservative: 0.09% Sodium azide
    Constituents: 0.33% Sodium phosphate, 0.88% Sodium chloride
  • Concentration information loading...
  • Purity
    IgG fraction
  • Clonality
    Polyclonal
  • Isotype
    IgG
  • Research areas

Applications

Our Abpromise guarantee covers the use of ab123975 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

Application Abreviews Notes
ELISA Use a concentration of 2.5 µg/ml.
Competitive ELISA Use a concentration of 2.5 µg/ml. 10ng/ml Warfarin produces 69% inhibition in a competitive ELISA employing ab123975
Purification Use a concentration of 2.5 µg/ml. ab123975 is suitable for the development of immunoaffinity purification columns.

Target

  • Relevance
    Warfarin, a synthetic derivative of coumarinan, is an anticoagulant medication used for the prophylaxis of thrombosis and embolism in many disorders. It was originally developed as a rat poison, and is still widely used as such, although warfarin-resistant rats are becoming more common. Warfarin inhibits the effective synthesis of biologically active forms of the vitamin K-dependent clotting factors: II, VII, IX and X, as well as the regulatory factors protein C, protein S and protein Z. Other proteins not involved in blood clotting, such as osteocalcin, may also be affected. The precursors of these factors require carboxylation of their glutamic acid residues to allow the coagulation factors to bind to phospholipid surfaces. This carboxylation is linked to oxidation of vitamin K to form Vitamin K epoxide, which is in turn recycled back to the reduced form by the enzyme epoxide reductase. Warfarin inhibits epoxide reductase, thereby diminishing vitamin K action and inhibiting production of functioning coagulation factors. As the body's stores of previously-produced factors degrade (over several days), the anticoagulation effect becomes apparent. The coagulation factors are produced, but have decreased functionality due to undercarboxylation; they are collectively referred to as PIVKAs (proteins induced [by] vitamin K absence/antagonism).

References

ab123975 has not yet been referenced specifically in any publications.

Customer reviews and Q&As

There are currently no Customer reviews or Questions for ab123975.
Please use the links above to contact us or submit feedback about this product.

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

Sign up